Peringatan Keamanan

Long-term toxicity studies to evaluate the carcinogenic, mutagenic and fertility impairment potential have not been conducted.FDA label

Isocarboxazid

DB01247

small molecule approved

Deskripsi

Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor.A31930 It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.T115 It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.

Struktur Molekul 2D

Berat 231.2505
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. The isocarboxazid half-life is of little interest as it is an irreversible monoamine oxidase inhibitor.[T117] These drugs present a very short half-life of 1.5-4 hours due to rapid hepatic metabolism.[T114]
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs are readily absorbed by the GI tract, present a low bioavailability and reach peak concentrations in 1-2 hours.T114

Metabolisme

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs are rapidly metabolized by acetylation in the liver.T114 As part of the metabolism, hippuric acid is a major metabolite.T117

Rute Eliminasi

Most of the eliminated dose is found in the urine, accounting for the 42.5% of the administered dose after 24 hours. From this amount, 75% of the renally eliminated drug is in the form of hippuric acid. Another section of the eliminated dose is observed through the intestinal tract and it accounts for 22% of the administered dose after 24 hours.A31942

Interaksi Makanan

3 Data
  • 1. Avoid alcohol. The official product labeling suggests avoiding the use of CNS depressants.
  • 2. Avoid tyramine-containing foods and supplements. Foods that contain tyramine include yogurt, aged cheese, ripe bananas, wine, and sourdough bread.
  • 3. Limit caffeine intake.

Interaksi Obat

1337 Data
Risperidone Isocarboxazid may increase the hypotensive activities of Risperidone.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Isocarboxazid.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Isocarboxazid.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Isocarboxazid.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Isocarboxazid.
Magnesium sulfate The therapeutic efficacy of Isocarboxazid can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Isocarboxazid may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Isocarboxazid.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Isocarboxazid.
Orphenadrine Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Isocarboxazid.
Pramipexole Isocarboxazid may increase the sedative activities of Pramipexole.
Ropinirole Isocarboxazid may increase the sedative activities of Ropinirole.
Rotigotine Isocarboxazid may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Isocarboxazid.
Sodium oxybate Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Thalidomide Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Desmopressin The risk or severity of hypertension can be increased when Desmopressin is combined with Isocarboxazid.
Cyclosporine The risk or severity of hypertension can be increased when Cyclosporine is combined with Isocarboxazid.
Icosapent The risk or severity of hypertension can be increased when Icosapent is combined with Isocarboxazid.
Mesalazine The risk or severity of hypertension can be increased when Mesalazine is combined with Isocarboxazid.
Indomethacin The risk or severity of hypertension can be increased when Indomethacin is combined with Isocarboxazid.
Methylergometrine The risk or severity of hypertension can be increased when Methylergometrine is combined with Isocarboxazid.
Nabumetone The risk or severity of hypertension can be increased when Nabumetone is combined with Isocarboxazid.
Ketorolac The risk or severity of hypertension can be increased when Ketorolac is combined with Isocarboxazid.
Tenoxicam The risk or severity of hypertension can be increased when Tenoxicam is combined with Isocarboxazid.
Celecoxib The risk or severity of hypertension can be increased when Celecoxib is combined with Isocarboxazid.
Tolmetin The risk or severity of hypertension can be increased when Tolmetin is combined with Isocarboxazid.
Rofecoxib The risk or severity of hypertension can be increased when Rofecoxib is combined with Isocarboxazid.
Piroxicam The risk or severity of hypertension can be increased when Piroxicam is combined with Isocarboxazid.
Fenoprofen The risk or severity of hypertension can be increased when Fenoprofen is combined with Isocarboxazid.
Valdecoxib The risk or severity of hypertension can be increased when Valdecoxib is combined with Isocarboxazid.
Diclofenac The risk or severity of hypertension can be increased when Diclofenac is combined with Isocarboxazid.
Sulindac The risk or severity of hypertension can be increased when Sulindac is combined with Isocarboxazid.
Nicergoline The risk or severity of hypertension can be increased when Nicergoline is combined with Isocarboxazid.
Flurbiprofen The risk or severity of hypertension can be increased when Flurbiprofen is combined with Isocarboxazid.
Etodolac The risk or severity of hypertension can be increased when Etodolac is combined with Isocarboxazid.
Mefenamic acid The risk or severity of hypertension can be increased when Mefenamic acid is combined with Isocarboxazid.
Naproxen The risk or severity of hypertension can be increased when Naproxen is combined with Isocarboxazid.
Sulfasalazine The risk or severity of hypertension can be increased when Sulfasalazine is combined with Isocarboxazid.
Phenylbutazone The risk or severity of hypertension can be increased when Phenylbutazone is combined with Isocarboxazid.
Meloxicam The risk or severity of hypertension can be increased when Meloxicam is combined with Isocarboxazid.
Carprofen The risk or severity of hypertension can be increased when Carprofen is combined with Isocarboxazid.
Phenmetrazine The risk or severity of hypertension can be increased when Phenmetrazine is combined with Isocarboxazid.
Diflunisal The risk or severity of hypertension can be increased when Diflunisal is combined with Isocarboxazid.
Salicylic acid The risk or severity of hypertension can be increased when Salicylic acid is combined with Isocarboxazid.
Meclofenamic acid The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Isocarboxazid.
Oxaprozin The risk or severity of hypertension can be increased when Oxaprozin is combined with Isocarboxazid.
Ketoprofen The risk or severity of hypertension can be increased when Ketoprofen is combined with Isocarboxazid.
Balsalazide The risk or severity of hypertension can be increased when Balsalazide is combined with Isocarboxazid.
Ibuprofen The risk or severity of hypertension can be increased when Ibuprofen is combined with Isocarboxazid.
Dutasteride The risk or severity of hypertension can be increased when Dutasteride is combined with Isocarboxazid.
Propafenone The risk or severity of hypertension can be increased when Propafenone is combined with Isocarboxazid.
Finasteride The risk or severity of hypertension can be increased when Finasteride is combined with Isocarboxazid.
Lumiracoxib The risk or severity of hypertension can be increased when Isocarboxazid is combined with Lumiracoxib.
Ephedrine The risk or severity of hypertension can be increased when Isocarboxazid is combined with Ephedrine.
Magnesium salicylate The risk or severity of hypertension can be increased when Isocarboxazid is combined with Magnesium salicylate.
Salsalate The risk or severity of hypertension can be increased when Isocarboxazid is combined with Salsalate.
Choline magnesium trisalicylate The risk or severity of hypertension can be increased when Isocarboxazid is combined with Choline magnesium trisalicylate.
Antrafenine The risk or severity of hypertension can be increased when Isocarboxazid is combined with Antrafenine.
Aminophenazone The risk or severity of hypertension can be increased when Isocarboxazid is combined with Aminophenazone.
Antipyrine The risk or severity of hypertension can be increased when Isocarboxazid is combined with Antipyrine.
Tiaprofenic acid The risk or severity of hypertension can be increased when Isocarboxazid is combined with Tiaprofenic acid.
Etoricoxib The risk or severity of hypertension can be increased when Isocarboxazid is combined with Etoricoxib.
Epicaptopril The risk or severity of hypertension can be increased when Isocarboxazid is combined with Epicaptopril.
Taxifolin The risk or severity of hypertension can be increased when Isocarboxazid is combined with Taxifolin.
Oxyphenbutazone The risk or severity of hypertension can be increased when Isocarboxazid is combined with Oxyphenbutazone.
1-benzylimidazole The risk or severity of hypertension can be increased when Isocarboxazid is combined with 1-benzylimidazole.
Benoxaprofen The risk or severity of hypertension can be increased when Isocarboxazid is combined with Benoxaprofen.
Metamizole The risk or severity of hypertension can be increased when Isocarboxazid is combined with Metamizole.
Zomepirac The risk or severity of hypertension can be increased when Isocarboxazid is combined with Zomepirac.
Dronedarone The risk or severity of hypertension can be increased when Isocarboxazid is combined with Dronedarone.
Cimicoxib The risk or severity of hypertension can be increased when Isocarboxazid is combined with Cimicoxib.
Amibegron The risk or severity of hypertension can be increased when Isocarboxazid is combined with Amibegron.
Nylidrin The risk or severity of hypertension can be increased when Isocarboxazid is combined with Nylidrin.
Solabegron The risk or severity of hypertension can be increased when Isocarboxazid is combined with Solabegron.
Lornoxicam The risk or severity of hypertension can be increased when Isocarboxazid is combined with Lornoxicam.
Aceclofenac The risk or severity of hypertension can be increased when Isocarboxazid is combined with Aceclofenac.
Zaltoprofen The risk or severity of hypertension can be increased when Isocarboxazid is combined with Zaltoprofen.
Saralasin The risk or severity of hypertension can be increased when Isocarboxazid is combined with Saralasin.
Azapropazone The risk or severity of hypertension can be increased when Isocarboxazid is combined with Azapropazone.
Parecoxib The risk or severity of hypertension can be increased when Isocarboxazid is combined with Parecoxib.
Salicylamide The risk or severity of hypertension can be increased when Isocarboxazid is combined with Salicylamide.
Tyramine The risk or severity of hypertension can be increased when Isocarboxazid is combined with Tyramine.
Mirabegron The risk or severity of hypertension can be increased when Isocarboxazid is combined with Mirabegron.
Adrafinil The risk or severity of hypertension can be increased when Isocarboxazid is combined with Adrafinil.
Kebuzone The risk or severity of hypertension can be increased when Isocarboxazid is combined with Kebuzone.
Isoxicam The risk or severity of hypertension can be increased when Isocarboxazid is combined with Isoxicam.
Indoprofen The risk or severity of hypertension can be increased when Isocarboxazid is combined with Indoprofen.
Ibuproxam The risk or severity of hypertension can be increased when Isocarboxazid is combined with Ibuproxam.
Floctafenine The risk or severity of hypertension can be increased when Isocarboxazid is combined with Floctafenine.
Fenbufen The risk or severity of hypertension can be increased when Isocarboxazid is combined with Fenbufen.
Etofenamate The risk or severity of hypertension can be increased when Isocarboxazid is combined with Etofenamate.
Etilefrine The risk or severity of hypertension can be increased when Isocarboxazid is combined with Etilefrine.
Epirizole The risk or severity of hypertension can be increased when Isocarboxazid is combined with Epirizole.
Benzydamine The risk or severity of hypertension can be increased when Isocarboxazid is combined with Benzydamine.

Target Protein

Amine oxidase [flavin-containing] A MAOA
Amine oxidase [flavin-containing] B MAOB

Referensi & Sumber

Artikel (PubMed)
  • PMID: 3069879
    Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE: A trial of isocarboxazid in the treatment of bulimia nervosa. J Clin Psychopharmacol. 1988 Dec;8(6):391-6.
  • PMID: 13864836
    BARBER JM, MURPHY FM, CHEESEMAN EA: A clinical trial of isocarboxazid ('marplan') in angina pectoris. Br Heart J. 1962 Mar;24:192-4.
  • PMID: 13749111
    SCHWARTZ MA: The metabolism of isocarboxazid (marplan) in the rat. J Pharmacol Exp Ther. 1960 Oct;130:157-65.
Textbook
  • Institute of Medicine (US) Council on Health Care Technology (1994). Medical Technology Assessment Directory (2nd ed.). American Medical Association Drug Evaluation.
  • Owens D. (2010). Companion to psychiatric studies (8th ed.). Elsevier.
  • Schatzberg A. and Nemeroff C. (2009). The american psychiatric publishing textbook of psychopharmacology (4th ed.). American Psychiatric Publishing Inc..

Contoh Produk & Brand

Produk: 2 • International brands: 2
Produk
  • Marplan
    Tablet • 10 mg/1 • Oral • US
  • Marplan
    Tablet • 10 mg/1 • Oral • US • Approved
International Brands
  • Enerzer — Takeda
  • Isocarboxazid — Alliance

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul